Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Vikman, Sofia; Sommaggio, Roberta; Torre, Manuel de la; Öberg, Kjell; Essand, Magnus; Giandomenico, Valeria; Loskog, Angelica; Tötterman, Thomas H.

doi:10.1080/02841860802438495

Cited by 38 publications

(38 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an exploratory study of 68 patients with GE-NETs, increased frequencies of circulating Tregs were demonstrated and, compared with those of healthy donors, a decreased proliferative capacity of T cells and reduced levels of Th1-promoting cytokines were observed (Vikman et al 2009). This means that therapeutic strategies are needed to overcome tumour-induced immune suppression.…”

Section: Avoiding Immune Destructionmentioning

confidence: 99%

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Walenkamp¹,

Crespo²,

Maya³

et al. 2014

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

In the past few years, there have been advances in the treatment of neuroendocrine tumours (NETs) and improvements in our understanding of NET biology. However, the benefits to patients have been relatively modest and much remains yet to be done. The 'Hallmarks of Cancer', as defined by Hanahan and Weinberg, provide a conceptual framework for understanding the aberrations that underlie tumourigenesis and to help identify potential targets for therapy. In this study, our objective is to review the major molecular characteristics of NETs, based on the recently modified 'Hallmarks of Cancer', and highlight areas that require further research.

show abstract

Section: Avoiding Immune Destructionmentioning

confidence: 99%

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Walenkamp¹,

Crespo²,

Maya³

et al. 2014

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…That an immune response opposes to NETs is also substantiated by the frequent finding of lymphocyte infiltration of NETs, as assessed by immunohistochemistry for CD3 (a general T lymphocyte marker), CD4, and CD8 [61,62,63]. In the biggest case series analyzed so far, CD3+ T cells were found to infiltrate 68% of 87 well-differentiated pancreatic NETs.…”

Section: Immune Response To Nets: the Other Side Of The Coinmentioning

confidence: 99%

“…In a subgroup of 25 patients compared with 18 controls, serum levels of the cytotoxic T lymphocyte-promoting cytokines IL-12p70 and IL-1β were significantly lower, and concentrations of the Treg cytokine TGF-β were increased, even though not significantly. After polyclonal activation, patients’ T cells proliferated less than those from controls, possibly because of an anergized state caused by carcinoid-associated Treg [62]. NET-infiltrating Treg have been detected by immunohistochemistry for single Treg markers [62,63], even though such an approach is not optimal to identify Treg and no Treg within NETs have been reported too [61].…”

Section: Immune Response To Nets: the Other Side Of The Coinmentioning

confidence: 99%

“…The number of circulating Treg was significantly higher in 68 patients with midgut carcinoid tumors than in 53 healthy blood donors [62]. In a subgroup of 25 patients compared with 18 controls, serum levels of the cytotoxic T lymphocyte-promoting cytokines IL-12p70 and IL-1β were significantly lower, and concentrations of the Treg cytokine TGF-β were increased, even though not significantly.…”

Section: Immune Response To Nets: the Other Side Of The Coinmentioning

confidence: 99%

See 1 more Smart Citation

Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New?

Ameri

Ferone²

2012

Neuroendocrinology

View full text Add to dashboard Cite

During the last two decades, research into the modulation of immunity by the neuroendocrine system has flourished, unravelling significant effects of several neuropeptides, including somatostatin (SRIH), and especially cortistatin (CST), on immune cells. Scientists have learnt that the diffuse neuroendocrine system can regulate the immune system at all its levels: innate immunity, adaptive immunity, and maintenance of immune tolerance. Compelling studies with animal models have demonstrated that some neuropeptides may be effective in treating inflammatory disorders, such as sepsis, and T helper 1-driven autoimmune diseases, like Crohn’s disease and rheumatoid arthritis. Here, the latest findings concerning the neuroendocrine control of the immune system are discussed, with emphasis on SRIH and CST. The second part of the review deals with the immune response to neuroendocrine tumors (NETs). The anti-NET immune response has been described in the last years and it is still being characterized, similarly to what is happening for several other types of cancer. In parallel with investigations addressing the mechanisms by which the immune system contrasts NET growth and spreading, ground-breaking clinical trials of dendritic cell vaccination as immunotherapy for metastatic NETs have shown in principle that the immune reaction to NETs can be exploited for treatment.

show abstract

“…Patienten mit NET des Mitteldarms zeigen (Vikman et al 2008(Vikman et al , 2009 Differenzierung nicht bestimmbar war, wurden in die Kategorie "diffus" eingeordnet.…”

Section: Das Konzept Des Tumorstromasunclassified

Tumormikroenvironment in Neuroendokrinen Tumoren (NET) des gastroentero-pankreatischen Systems

Skupin¹,

Fuezesi²,

Cameron³

2013

Z Gastroenterol

View full text Add to dashboard Cite

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

Cited by 38 publications

References 45 publications

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment

Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New?

Tumormikroenvironment in Neuroendokrinen Tumoren (NET) des gastroentero-pankreatischen Systems

Contact Info

Product

Resources

About